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Summary 
In normal human fibroblasts, cyclin A-CDK2 exists in 
a quaternary complex that contains p21 and PCNA. In 
many transformed cells, p21 disappears, and a sub- 
stantial fraction of cyclin A-CDK2 complexes with 
p9 cKsl/cKs2, p19, and p45. To investigate the signifi- 
cance of these rearrangements, we have isolated 
cDNAs encoding p19 and p45. In vitro reconstitution 
demonstrated that binding of p19 to cyclin A-CDK2 
requires p45. Addition of these proteins to the kinase 
had no substantial effect on the kinase activity in vitro. 
Interference with p45 function in vivo by microinjec- 
tion of antibodies or antisense oligonucleotides pre- 
vented entry into S phase in both normal and trans- 
formed cells. Cyclin A-CDK2 has previously been 
identified as a kinase whose activity is essential for S 
phase. Our results identify p45 as an essential element 
of this activity. The abundance of p45 is greatly in- 
creased in many transformed cells. This could result 
in changes in cell cycle control that contribute to the 
process of cellular transformation. 
Introduction 
In eukaryotes, entry into each phase of the cell division 
cycle is controlled by a class of enzymes known as the 
cyclin-dependent kinases (CDKs) (reviewed by Sherr, 
1993, 1994; Hunter and Pines, 1994). In their simplest 
active form, these consist of a catalytic subunit (the CDK) 
and a positive regulatory subunit known as a cyclin. In 
mammalian cells, the CDK family consists of at least seven 
members. Combination with an equally diverse family of 
cyclins yields numerous cell cycle regulatory enzymes, 
each with a potentially unique function. 
Considering the role of CDKs in controlling cell prolifera- 
tion, it is not surprising that these enzymes are subject to 
multiple levels of regulation. First, the activity of CDKs 
depends upon the availability of their cognate cyclin sub- 
units, many of which either oscillate in abundance during 
the cell cycle or require the presence of growth factors 
for expression (reviewed by Sherr, 1993). Once formed, 
cyclin-CDK complexes still require phosphorylation of a 
threonine residue (usually near amino acid 160) for activity 
(reviewed by Solomon, 1993; Dunphy, 1994). Active en- 
zymes can be further egulated by inhibitory phosphoryla- 
tion (e.g., of Thr-14 and Tyr-15 in cdc2) and by binding of 
inhibitory proteins (e.g., p21 or p16) (reviewed by Hunter 
and Pines, 1994; Xiong et al., 1993b; Harper et al., 1993; 
Serrano et al., 1993). 
Differences in the abilities of normal and transformed 
cells to proliferate had long predicted that alterations in 
the pathways that control cell cycle progression must ac- 
company cellular transformation. This prompted a com- 
parison of cyclin-CDK complexes present in normal fibro- 
blasts to those present in their transformed derivatives 
(Xiong et al., 1993a). In normal cells, each cyclin-CDK 
enzyme exists in a quaternary complex that also contains 
proliferating cell nuclear antigen (PCNA) and p21 (Zhang 
et al., 1993). Quaternary complexes are lost from many 
transformed cells owing to the absence of the tumor sup- 
pressor p53, which directly controls the expression of p21 
(Xiong et al., 1993a; EI-Deiry et al., 1993). In the presence 
of DNA damage, elevation of p53 levels leads to the accu- 
mulation of p21 (Dulie et al., 1994; EI-Deiry et al., 1994), 
which acts as an inhibitor of cyclin-CDK enzymes when 
bound at greater than unit stoichiometry (Zhang et al., 
1994). 
In normal cells, CDK4 and CDK6 partner with D-type 
cyclins in quaternary complexes (Matsushime t al., 1992; 
Xiong et al., 1992; Zhang et al,, 1993; Meyerson and Har- 
low, 1994). However, in virally transformed cells, a 16 kDa 
protein, p16, is the exclusive partner of these kinase sub- 
units (Xiong et al., 1993a). The critical role for CDK4 and 
CDK6 in cell cycle progression is to phosphorylate the 
tumor suppressor pRb and consequently permit he transi- 
tion from G 1 into S phase (Matsushime t al., 1994; Meyer- 
son and Harlow, 1994). p16 is a specific inhibitor of CDK4 
and CDK6 whose effect would normally be to halt cell cycle 
progression (Serrano et al., 1993, 1994). However, in the 
virally transformed cells, pRb function is compromised, 
and p16 is therefore without effect (Xiong et al., 1993a; 
Serrano et al., 1994). 
Our original comparisons of cyclin kinase complexes in 
normal and transformed fibroblasts also identified a third 
class of subunit rearrangements that specifically affected 
cyclin A-CDK2 complexes (Xiong et al., 1993a). In many 
transformed cells, a cyclin A-CDK2 complex(es) con- 
taining proteins of 9, 19, and 45 kDa replaces the quater- 
nary cyclin A-CDK2-p21-PCNA complexes found in nor- 
mal cells (see below). 
Cyclin A-associated enzymes have been established 
as key promoters of progression through the S phase of 
the cell cycle (reviewed by Heichman and Roberts, 1994). 
The expression of cyclin A and the activity of cyclin A-CDK2 
peaks during late G1 and S phase in both normal and 
transformed cells (Pines and Hunter, 1990). Furthermore, 
microinjection of antibodies to cyclin A or introduction of 
antisense cyclin A expression constructs can prevent DNA 
replication (Girard et al., 1991; Pagano et al., 1992). In 
some cell types, cyclin A has even been shown to localize 
to sites of ongoing DNA synthesis (Cardoso et al., 1993). 
Finally, ectopic expression of cyclin A was sufficient to 
allow adhesion independent DNA synthesis in normal rat 
kidney cells (Guadagno et al., 1993). 
Thus far, our studies of the rearrangements of cyctin 
kinase complexes that occur upon cellular transformation 
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have identified at least two direct links between tumor sup- 
pression and the enzymes that regulate cell cycle progres- 
sion. p21 is a direct transcriptional target of the tumor 
suppressor p53 and is a likely effector of the cell cycle 
arrest that is induced by p53 in response to DNA damage 
(EI-Deiry et al., 1993, 1994; Duli~ et al., 1994). The p16 
protein is a major tumor suppressor in its own right and 
acts in a regulatory pathway that also contains another 
tumor suppressor, pRb, and an oncogene, cyclin D (re- 
viewed by Hunter and Pines, 1994). In this paper, we de- 
scribe the isolation of cDNAs encoding the 19 and 45 kDa 
subunits of the cyclin A-CDK2 complex that is abundant 
in tumor cells. Our data suggest that the p45-bound form 
of cyclin A-CDK2 is required for execution of DNA replica- 
tion in both normal and transformed cells. 
Results 
Cyclin A-CDK2 Complexes Differ in Normal 
and Transformed Cells 
In normal human fibroblasts, cyclin A-CDK2 exists in a 
quaternary complex with p21 and PCNA (Zhang et al., 
1993). We have previously reported the dissolution of this 
complex in fibroblasts transformed by viral oncoproteins 
(Xiong et al., 1993a). In these cells, cyclin A instead com- 
plexes with CDK2 and proteins of 9, 19, and 45 kDa (p9, 
p19, and p45) (Figure 1). These proteins are the predomi- 
nant partners for cyclin A not only in virally transformed 
cells (e.g., HeLa and 293; Figure 1) but also in many trans- 
formed cells that express no viral oncoprotein (e.g., ML1 ; 
Figure 1A). Under no circumstances have we observed 
p19 or p45 in association with other cyclin-CDK com- 
plexes (data not shown). However, p9 can also be found 
in cyclin B-CDC2 immunoprecipitates (data not shown). 
Since p9, p19, and p45 invariably appear together in 
cyclin A immunoprecipitates, we considered the possibility 
that these proteins might exist, with CDK2, in a single 
complex. To test this possibility, proteins present in a ly- 
sate prepared from ~S-labeled 293 cells were separated 
by sedimentation in a glycerol gradient. Cyclin A and its 
associated proteins were recovered from each fraction of 
the gradient by immunoprecipitation with a cyclin A antise- 
rum. Peak levels of p9, pl 9, and p45 were found in fraction 
17, which also contained substantial amounts of cyclin A 
and CDK2 (Figure 1B). This strongly suggested that these 
five proteins coexist in a single complex. Western blotting 
demonstrated that the p19-p45-containing complex was 
well resolved from the cyclin A-CDK2 complex that con- 
tains p107 and E2F (peaked in fraction 25; data not shown). 
Cyclin A-CDK2 complexes are active from the onset of 
S phase through G2 phase and into early M phase, at 
which point the complex is inactivated by degradation of 
cyclin A. To gain some clue to the function of the p19- 
p45-containing complex, we asked whether its abun- 
dance varied during the cell cycle. Treatment of HeLa cells 
with nocodazole, a drug that causes arrest in late G2/early 
M phase, reduced the amount of p19 and p45 in cyclin A 
immunoprecipitates (data not shown). However, synchro- 
nization of HeLa cells in S phase by treatment with hy- 
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Figure 1. The Presence of Two Types of Cyclin A-CDK2 Complexes 
in Transformed and Nontransformed Cells 
(A) Comparison of cyclin A-CDK2 complexes between transformed 
and nontransformed cells. Cell lysates from either [35S]methionine- 
labeled, nontransformed human fibroblasts (Wl38, IMR90, and Hs68) 
or transformed cells (293, ML1, and HeLa) were immunoprecipitated 
with either normal rabbit serum (NRS), anti-cyclin A (anti-Cyc A), or 
anti-CDK2 antibodies or with the anti-CDK2 antibody plus CDK2 anti- 
genic peptide as indicated. The electrophoretic positions of cyclin A 
and CDK2-associated proteins are indicated on the right. The protein 
molecular mass markers (in kilodaltons) are indicated on the left. 
(B) Glycerol gradient analysis of quinary cyclin A-CDK2-p9-p19-p45 
protein complex. Cell lysate from [3SS]methionine-labeled 293cells 
was loaded directly onto a 15%-35% glycerol gradient nd sedi- 
mented. The fractions (250 ~.1 each) were collected from the top (left) 
to bottom (right) of the gradient. Cyclin A (cyc A) complexes were 
recovered from the fractions by cyclin A antibody and analyzed by 
SDS-polyacylamide gel electrophoresis (SDS-PAGE). The peak of 
bovine serum albumin, sedimented in parallel as molecular mass 
marker, migrates at fraction 15. 
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droxyurea resulted in a dramatic increase in cyclin A-bound 
p9, p19, and p45 (data not shown). These results sug- 
gested that the relative abundance of the cyclin A-CDK2- 
p9-p19-p45 complex was increased during S phase. 
Isolation of cDNA Clones That Encode p19 and p45 
As a prerequisite to understanding the consequences of 
the association of p9, p19, and p45 with cyclin A in trans- 
formed cells, it was necessary to identify the protein con- 
stituents of this complex. The mobility of p9 was reminis- 
cent of previously characterized CDK-associated proteins, 
p9 cKsl and p9 cKs2 (Richardson et al., 1990). These homo- 
logs of fission yeast p13 s"°~ have been shown to bind to 
CDKs in mammalian cells. A partial V8 protease digest of 
the cyclin A-associated p9 was virtually identical to similar 
digests of in vitro translated CKS1 or CKS2 (data not 
shown), indicating that the cyclin A-associated p9 was a 
member of the human CKS family. However the high de- 
gree of amino acid identity between CKS1 and CKS2 made 
it impossible to determine whether the cyclin A-associated 
p9 was identical to either CKS1 or CKS2 or was instead 
a mixture of the two. 
Neither p19 nor p45 had a mobility that was identical 
to a known CDK-associated protein. We therefore sought 
to isolate cDNAs encoding these potentially uncharacter- 
ized components of cyclin A-CDK2. Cyclin A and its asso- 
ciated proteins were purified from lysates of human 293 
cells using an anti-cyclin A immunoaffinity column. Pro- 
teins were eluted from the affinity matrix by boiling in 
Laemmli's sample buffer. Individual proteins present in the 
eluent were separated on a preparative SDS-polyacryl- 
amide gel. Bands corresponding to p19 and p45 were ex- 
cised from the gel, and the proteins were digested in situ 
with achromobacter endoprotease I. Following elution 
from the gel, individual peptide fragments from each pro- 
tein were purified using high pressure liquid chromatogra- 
phy and sequenced by an automated peptide sequencer. 
Sequences of several peptides were obtained from each 
protein (Figures 2A and 2B). 
The sequences of the p19 and p45 peptides were used 
to design degenerate oligonucleotide primers. These were 
used to amplify fragments of the p19 and p45 cDNAs from 
a HeLa cell library. In each case, the fragments contained 
sequences encoding other p19 or p45 peptides obtained 
from protein sequencing. Therefore, the fragments were 
used as probes to identify full-length cDNAs encoding can- 
didate p19 and p45 proteins. 
The cDNA encoding the candidate for pl 9 contained an 
open reading frame of 163 amino acid residues corre- 
sponding to a protein with a calculated molecular mass 
of 18,645 Da (Figure 2B). The deduced amino acid se- 
quence of p19 indicated that it was not a member of the 
p21 family. A search of available databases revealed no 
significant homology to any protein with a clearly defined 
function (see below). 
In vitro translation of the candidate p19 cDNA produced 
a protein with an electrophoretic mobility identical to that 
of the p19 present in an anti-cyclin A immunoprecipitate 
from 293 cells (Figure 3A, left). A comparison of a partial 
V8 protease digest of the in vitro translated p19 to a similar 
digest of p19 from a cyclin A immunoprecipitate confirmed 
that our cDNA encoded a complete p19 protein (data not 
shown). A similar approach was used to verify our candi- 
date p45 cDNA (Figure 3A). 
The p45 cDNA encoded a polypetide of 435 amino acids 
with a calculated molecular mass of 48,928 Da (see Figure 
2A). As with p19, a search of available databases yielded 
no informative homologies. However, this search did re- 
veal that the carboxy-terminal half of the p45 protein is 
composed of seven imperfect repeats of 26 amino acid 
residues (see Figure 2C). This motif shares homology with 
the leucine-rich repeats that are found in a number of func- 
tionally diverse proteins, including adenylate cyclase, 
SDS22, and the RAD7 proteins of Saccharomyces cere- 
visiae and Schizosaccharomyces pombe (Kataoka and 
Wigler, 1985; Perozzi and Prakash, 1986; Ohkura and Ya- 
nagida, 1991). The leucine-rich repeated motifs are thought 
to be involved in protein-protein interactions (Kobe and 
Deisenhofer, 1994). 
Since p19 and p45 are previously unreported proteins 
that associate with the cyclin A-CDK2 preferentially during 
S phase in transformed cells, we have named them pl 9 skpl 
and p45 skp2 (for S phase kinase-associated protein). 
p19, Cyclin A, and CDK2 Are the Major 
p45-Associated Proteins 
To examine p19 and p45 protein complexes in vivo, we 
used specific antibodies raised against p45 and p19 pro- 
teins. Immunoprecipitation of p45 from [35S]methionine- 
labeled 293 cell lysates revealed that cyclin A, CDK2, p9, 
and p19 are the major p45-associated proteins in human 
cells (Figure 3C, lane labeled anti-p45). This cyclin A-CDK2- 
pg-p19-p45 complex was an active kinase capable of 
phosphorylating histone H1 (Figure 3C). 
The cyclin A-CDK2-p19-p45 complex was initially iden- 
tified as a major cyclin A-CDK2 complex in many trans- 
formed cells (see Figure 1). However, p45 was also pres- 
ent at low level in normal human fibroblasts (Figure 3B). 
As in transformed cells, p45 in normal cells associates 
with cyclin A and CDK2 (Figure 3B). 
Using a p19 antiserum, we did not recover cyclin A, 
CDK2, or p45 in the immunoprecipitates (Figures 3B and 
3C). Furthermore, we could not detect any histone H1 ki- 
nase activity in the anti-p19 immunoprecipitates. This indi- 
cated either that the p19 antiserum did not recognize the 
complexed form of p19 or that the vast majority of p19 in 
human cells is not bound to the cyclin A-CDK2 enzyme. 
Reconstitution of Cyclin A-CDK2-p19-p45 
Complexes 
To examine the biochemical consequences of complex 
formation between cyclin A-CDK2 and p9, p19, and p45, 
we performed in vitro reconstitution experiments using 
proteins expressed in baculovirus-infected insect cells. 
Addition of p45 alone to cyclin A-CDK2 resulted in the 
formation of a ternary complex (Figure 4A). p45 could also 
bind cyclin A alone, but to a much lower extent than in 
the presence of CDK2. 
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1570 1590 
CTGTCATTCTGC~GTATACTAGGGAGCCCATTTTGAGAG 
The p19 protein could not independently associate with 
cyclin A-CDK2 in vitro. However, binding of p19 was ob- 
served in the presence of p45 (Figure 4A, right), sug- 
gesting that p45 mightbridge the interaction between p19 
and cyclin-CDK complexes. In agreement with this model, 
p19 and p45 can form an independent binary complex 
(data not shown), p9 cKsl or p9 cKs2 was capable of joining 
cyclin A-CDK2 irrespective of the presence of p45 or pl 9. 
However, p9 itself had no measurable effect on the ability 
of p45 or p19 to bind cyclin A complexes (data not shown). 
Using complexes reconstituted in vitro, we have asked 
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Figure 2. The DNA and the Deduced Amino Acid Sequences of p19 
and p45 
(A) DNA and the deduced amino acid sequences of p45. The peptides 
that were obtained from microsequencing of the purified p45 protein 
are underlined. 
(B) DNA and the deduced amino acid sequences of pl 9. The peptides 
that were obtained from microsequencing of the purified p19 protein 
are underlined. 
(C) p45 contains a leucine-rich repeated domain at its carboxyl region. 
whether binding of p45 alone or of p45 and p19 had any 
effect on the enzymatic activity of cyclin A-CDK2. Even 
at saturating concentrations of p45 or both p45 and p19, 
we observed no discernible change in the ability of cyclin 
A-CDK2 to phosphorylate several candidate substrates 
such as histone H1, the tumor suppressor pRb, or the 
34 kDa subunit of the eukaryotic single-stranded binding 
protein, replication protein A (RPA) (Figure 4A; data not 
shown). This is consistent with the observation that the 
cyclin A -CDK2-p9-p19-p45  complexes isolated from h u- 
man cells contained an active kinase (see Figure 3C). 
Proteins that are associated with cyclin-CDK com- 
plexes could be either regulators or substrates of these 
kinases. We therefore tested whether p45 or p19 could 
serve as a substrate for cyclin A-CDK2. Glutathione S-trans- 
ferase (GST)-p45 fusion protein (Figure 4B, left), but not 
purified GST (data not shown), was phosphorylated by 
purified cyclin A-CDK2 (Figure 4B, right). Phosphorylation 
of p45 was also detected upon addition of [7-32P]ATP to 
cyclin A immunoprecipitates from human cells (data not 
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Figure 3. Comparison of Cloned p19 and p45 
with the Cyclin A-CDK2 Complex-Associated 
Proteins 
(A) (Left) The in vitro translated (IVT) candidate 
p19 and p45 proteins from the cloned cDNAs 
were compared with those of p19 and p45 in 
anti-cyclin A (a-cyc A) immunoprecipitation 
from 293 cells. (Right) Specificity of affinity- 
purified p45 antibodies. Total cell lysates were 
prepared from HeLa cells arrested in S phase 
by 10 mM hydroxyurea. Approximately 75 p.g 
of total proteins were loaded onto an SDS-poly- 
acrylamide gel and electrophoresed as indi- 
cated. The recombinant p45 protein (approxi- 
mately 25 ng) was also electrophoresed in 
parallel. The proteins were immunoblotted with 
the affinity-purified anti-p45 antibody. 
(B) Cyclin A-CDK2-p45 complexes were iso- 
lated from log phase-growing transformed 
cells (293) or normal human fibroblasts (Wl38) 
by immunoprecipitation (IP) with specific cyclin 
A (cyc A), CDK2, p19, and p45 antibodies, as 
indicated at the top of the lanes. The proteins 
were detected by immunoblot using either anti- 
p45 (upper set of gels) or anti-CDK2 (lower set 
of gels) antibodies. Double amounts of Wl38 
cells were used in the experiment. 
(C) In vivo p19-p45 complexes. Cell lysates 
from [~S]methionine-labeled 293 cells were im- 
munoprecipitated with specific cyclin A (cyc A), 
p45, or p19 antibodies. The immunoprecipi- 
tates were analyzed for either protein composi- 
tion (top) or kinase activity using histone H1 as 
the substrate (bottom). 
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Figure 4. p45 and p19 Complex with Cyclin 
A-CDK2 In Vitro 
(A) In vitro formation of cyclin A-CDK2-p19- 
p45 complex. (Left) Baculovirus-infected insect 
Sf9 cells were [3SS]methionine labeled. The cell 
lysates that contained cyclin A (cyc A) and 
CDK2 were incubated in the absence or pres- 
ence of p45 as indicated. The protein com- 
plexes were immunoprecipitated with anti- 
cyclin A antibody and assayed for both protein 
composition (top) and kinase activity (bottom) 
using histone H1 as the substrate. (Right) ~S- 
labeled insect Sf9 cell lysates that contain ei- 
ther cyclin A, CDK2, or p19 were mixed. To this 
mixture, increasing amounts of p45-containing 
Sf9 cell lysates (0, 5, 10, 20, and 40 p.I) were 
added as indicated. The protein complexes 
were immunoprecipitated with anti-cyclin A 
antibody. Both the protein composition and the 
histone H1 kinase activity were analyzed. 
(B) Phosphorylation of p45 by cyclin A-CDK2. 
(Left) Coomassie staining of the purified GST- 
p45 protein. The GST-p45 fusion protein was 
isolated from Sf9 cells infected by a baculovirus 
encoding the recombinant protein. (Right) 
Phosphorylation assay. Active cyclin A (cyc A)-CDK2 was assembled from lysates prepared from baculovirus infected insect Sf9 cells as described 
in (A). The kinase was isolated by anti-cyclin A immunoprecipitation. Purified GST-p45 protein was added to the purified cyclin A-CDK2 in the 
presence of [7-32P]ATP. The incorporation of 32p into p45 and cyclin A is shown. 
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shown). These studies suggest that the biological activity 
of p45 could be regulated by cyclin A-CDK2. In contrast, 
there was no detectable phosphorylation of p19 by cyclin 
A-CDK2 in these assays (data not shown). 
p45 Is Essential for Entry into S Phase 
Since neither p19 nor p45 had a negative effect on cyctin 
A-CDK2 activity in vitro, it seemed unlikely that either of 
these proteins would act as an inhibitor of cell proliferation 
in vivo, We therefore sought to determine whether the 
presence of p19 or p45 might be required for any aspect 
of cell cycle progression, particularly for entry into or pas- 
sage through S phase. We initially chose to interfere with 
p19 and p45 function by antibody microinjection. For these 
experiments, HeLa cells were synchronized by mitotic 
shake-off (Pagano et al., 1992). These cells enter S phase 
approximately 12-14 hr after replating on gridded cov- 
erslips. At approximately 6 hr after replating, cells were 
microinjected with affinity purified p19 or p45 antibodies 
or with purified GST antibodies as a control. Incorporation 
of bromodeoxyuridine (BrdU) was used to monitor DNA 
synthesis. 
Injection of cells with GST antibodies had no effect on 
the percentage of BrdU-positive cells (Figures 5G-51). 
However, injection of p45 antibodies everely reduced the 
fraction of cells that underwent DNA synthesis (Figures 
5A-5C). This antibody recognized only a single p45 pro- 
tein in the total HeLa cell lysates (see Figure 3A, right). 
To test further the specificity of the S phase inhibitory 
effect, we coinjected cells with p45 antibodies and with 
an equal molar amount of purified recombinant GST-p45 
protein (Figures 5D-5F). This resulted in a complete rever- 
sal of the inhibition of DNA synthesis (Figures 5D-5F). 
Cyclin A-CDK2 function is required both for entry into S 
phase and for ongoing DNA synthesis. To ask whether 
the requirement for p45 was similar to the requirement for 
cyclin A-CDK2, we injected p45 antibodies into cells that 
were synchronized in S phase. In this case, microinjection 
had no effect on the incorporation of BrdU (Figures 5J- 
5L), suggesting that p45 is required for entry into S phase 
but not for progression through S phase, 
As with the GST antibodies, microinjection of p19 anti- 
bodies was without effect (data not shown). Although this 
is somewhat at odds with the results of the p45 antibody 
injections, it may not be surprising in light of the fact that 
the p19 antibodies do not recognize the p19 protein in 
cyclin A-containing complexes (see Figure 3C). 
Although p45 is most abundant in tumor cells, it is also 
expressed to a low extent in normal cells (see Figure 3B). 
To determine whether these cells also require p45 function 
for entry into S phase, we again microinjected purified 
p45 antibody and measured the effect on DNA synthesis. 
Normal human fibroblasts were synchronized by serum 
starvation and were subsequently stimulated by serum 
addition to reenter the cell cycle. Microinjection of the p45 
antibody during G1 essentially abolished DNA synthesis 
(Figures 5M-50), whereas injection of the control GST 
antibody had no inhibitory effect (Figures 5P-5R). Again, 
coinjection of p45 protein with the p45 antibody completely 
rescued DNA synthesis (data not shown). These results 
suggest that p45 is required for execution of S phase in 
both normal and transformed cells. Furthermore, the abil- 
ity of p45 antibodies to inhibit DNA synthesis in normal 
cells strongly argues against the possibility that the p45 
antibody exerts its effect simply by interfering with the 
function of all cyclin A-CDK2 complexes since cyclin 
A-CDK2 is in vast excess over p45 in normal cells. 
As a complement o antibody microinjection, we have 
also injected synthetic antisense oligonucleotides that 
were directed against the p45 mRNA (Figure 6; data not 
shown). Microinjection of p45 antisense oligonucleotides 
into synchronized G1 HeLa cells prevented DNA synthesis 
(Figure 6), whereas a control oligonucleotide had no effect. 
The inclusion of purified p45 protein in the injection mix- 
ture completely reversed the inhibition of DNA synthesis 
(Figure 6). 
p45 Expression Is High in Transformed Cells 
and during S Phase 
Since the proportion p19-p45-containing cyclin A com- 
plexes is increased in transformed cells that have been 
blocked in S phase by treatment with hydroxyurea (data 
not shown), we asked whether p45 or p19 expression 
might vary during the cell cycle. HeLa cells were synchro- 
nized at the G1/S boundary by a double thymidine block 
(Heintz et al., 1983; Pines and Hunter, 1990). Following 
release from the second block, cells immediately entered 
S phase. They proceeded synchronously through G2/M 
after approximately t 0-12 hr and again entered S phase 
at 24-28 hr following release (Figure 7A). Northern blotting 
of RNA prepared from synchronous populations revealed 
that expression of the p45 mRNA was clearly cell cycle 
dependent (Figure 7A). Levels were high in S phase cells 
and lower in G1 and G2/M fractions. This pattern of expres- 
sion roughly paralleled that of cyclin A (Figure 7A). Expres- 
sion of p19 was also cell cycle dependent, with peak levels 
in S phase (Figure 7A). However, since pl 9 protein is pres- 
ent in excess of p45, it is unclear whether changes in p19 
levels contribute to the cell cycle dependence of p19- 
p45-containing complexes. 
Cyclin A complexes containing p19 and p45 are much 
more abundant in many transformed cells than in their 
normal counterparts. To begin to address the mechanisms 
that underlie these changes in the subunit composition of 
cyclin A-CDK2, we have examined patterns of p19 and 
p45 expression (Figure 7B). A comparison of several cell 
lines indicated that both p19 mRNA and p19 protein were 
equally abundant in normal and transformed cells. In con- 
trast, both p45 mRNA and p45 protein levels were greatly 
increased in transformed cell lines. Since the presence 
of p45 is necessary for binding of p19 to cyclin A-CDK2 
complexes (see Figure 4A), it is likely that changes in the 
abundance of the p45 protein contribute to the re- 
arrangement of cyclin A-CDK2 complexes that accom- 
pany cellular transformation. 
Discussion 
The principal characteristic of all transformed cells is their 
ability to proliferate under conditions that would arrest the 
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Figure 5. p45 Is Essential for S Phase Entry 
(A-I) Synchronized G1 phase HeLa cells were 
microinjected with either the affinity-purified 
anti-p45 antibody (A-C) or coinjected with anti- 
p45 antibody plus equal moles of purified p45 
protein (D-F) or with equal amount of a control 
antibody, the anti-GST antibody (G-I). The 
cells were then labeled with BrdU continuously 
for another 12-14 hr. 
(J-L) Synchronized S phase HeLa cells were 
microinjected with anti-p45 antibody. After 2 h r, 
the cells were labeled with BrdU for 6 hr. 
(M-R) Synchronized G1 human normal fibre- 
blast cells (IMR90) were microinjected with ei- 
ther anti-p45 (M-O) or anti-GST (P-R) antibod- 
ies. The cells were subsequently labeled with 
BrdU for 24 hr. 
The cells were fixed and processed for the 
staining of either the injected immunoglobulin 
G proteins (B, E, H, K, N, and Q)or the incorpo- 
ration of BrdU in the nuclei with an anti-BrdU 
antibody (C, F, I, L, O, and R). The phase- 
contrast photography of injected cells was also 
presented (A, D, G, J, M, and P). 
growth of their normal counterparts. Accumulating evi- 
dence suggests that loss of proliferation control in tumor 
cells is accompanied by changes in the regulation of the 
cyclin-CDK enzymes that drive cell cycle progression 
(Xiong et al., 1993a). In previous work, we have demon- 
strated that two major routes of CDK inhibition, those in- 
volving p16 and p21, are commonly compromised during 
cellular transformation. In this paper, we have examined 
changes in the cyclin A-CDK2 complex that also accom- 
pany cellular transformation. 
In normal cells, cyclin A-CDK2 exists predominantly in 
a quaternary complex with p21 and PCNA (Zhang et al., 
1993). In many transformed cells, these are replaced by 
quinary complexes containing cyclin A, CDK2, p9 cKsl or 
p9 cKs2, p19, and p45 (Figure 1). This switch may be ex- 
plained, in part, by the fact that p45 is more abundant in 
most transformed cells than in their normal precursors 
(Figures 3 and 7). Although p19 is equally abundant in 
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Figure 6. Summary of the Microinjection Experiments 
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Figure 7. Analysis of p19 and p45 Expression 
(A) (Top) Cell cycle analysis. HeLa cells were synchronized at the 
GI/S border by double thymidine block. Total RNAs were prepared 
at various timepoints after releasing the cells into fresh medium. The 
RNA blots were probed with either ~P-labeled p19, p45, cyclin A, or 
CDK2 cDNA as indicated. (Bottom) FACS analysis of synchronized 
cells. Open squares, S phase; open triangles, G2/M phase; closed 
circles, G1 phase. 
(B) Expression of p45 and p19 in transformed and nontransformed 
human cells. Total RNA was prepared from active growing nontrans- 
formed human fibroblasts (Wl38 and IMR90) or transformed cells 
(A431, ML1, HeLa, VA13, and 293). Equal amounts of RNA were used 
in each lane. The blots were probed with either s2p-labeled p45 or p19 
cDNA. 
normal and transformed cells (Figure 7B), the presence 
of p45 is required for binding of p19 to cyclin A-CDK2 
(Figure 4A), thus explaining the concerted appearance of 
these proteins in cyclin A-CDK2 complexes. We have also 
found that p45 and p21 compete for binding to the cyclin 
A-CDK2 enzyme (data not shown). Therefore, the loss 
of p21 may also contribute to the redistribution of cyclin 
A-CDK2 into the p45-containing complex that is enriched 
in transformed cells. 
Binding of p19 and p45 to cyclin A-CDK2 has no discern- 
ible effect on the ability of the kinase to phosphorylate 
histone H 1, Rb, or p34 RPA in vitro. However, in vivo ablation 
of p45 by microinjection of either p45 antibodies or anti- 
sense oligonucleotides clearly indicates that the p19- 
p45-containing complex plays a role in promoting cell cy- 
cle progression that is not only essential but is also distinct 
from that of the cyclin A-CDK2 binary enzyme (Figures 
5 and 6). Ablation of p45 in transformed cells prevented 
DNA synthesis. This was only effective if cells were in- 
jected prior to the onset of S phase. In normal cells, p45 
and p45-associated cyclin A complexes are quite low in 
abundance (Figures 1,.3, and 7). Nevertheless, injection 
of p45 antibody still prevented DNA synthesis (Figures 5 
and 6). In these cells, the binding of p45 to its antibody 
could affect only a small fraction of total cyclin A-CDK2 
enzyme. Therefore, that fraction must have a specific role 
in the promotion of S phase. 
Our studies do not rule out the possibility that p45 plays 
an essential role in the execution of DNA synthesis that 
is independent of its interaction with cyclin A-CDK2. How- 
ever, antibody depletion experiments demonstrate that 
>90% of the p45 present in 293 cell lysates is bound to 
cyclin A-CDK2 (data not shown). Considered together 
with the well-established role of cyclin A-CDK2 in S phase 
progression, our results argue that the requirement for 
p45 at the onset of DNA synthesis reflects a requirement 
for the p19-p45-bound cyclin A-CDK2 enzyme. Our re- 
sults also indicate that the biological activity of p45 may 
potentially be regulated by cyclin A-CDK2 through phos- 
phorylation (Figu re 4B). The binding of p45 could facilitate 
the phosphorylation of p45 by the kinase. 
Since p45 contains a leucine-rich repeat motif that is 
implicated in protein-protein interactions, p45 could func- 
tion as an adaptor for the cyclin A-CDK2 enzyme. Such 
a function has been suggested for Grb2, which binds to 
both the receptor tyrosine kinases and Sos or Shc proteins 
(Skolnik et al., 1993), and for SDS22, another leucine-rich 
repeat-containing protein that associates with phospha- 
tase PP1 in S. pombe (Ohkura and Yanagida, 1991). In 
this scenario, p45 could target he cyclin A-CDK2 to its 
specific substrates. 
To date, the sequence of p19 has provided no clues to 
the precise mechanism by which p19 functions. A search 
of the sequence database has revealed extensive homol- 
ogy between p19 and two ther published sequences. The 
first, A39L, shares approximately 50% amino acid identity 
with human p19. A39L is derived from the Chlorella virus 
that infects algae (Lu et al., 1995). This virus shares simi- 
larity to members of poxvirus family and encodes its own 
DNA replication machinery, including homologs of DNA 
polymerase ~z and PCNA (which shares only 29% identity 
with its human counterpart) (Grabherr et al., 1992; J. L. 
Van Etten, personal communication). The pl 9 protein also 
shares 65% amino acid identity with a protein, FP21, from 
Dictyostelium (Kozarov et al., 1995). Since neither the 
function of A39L nor the function of FP21 is known, these 
homologies have been somewhat uninformative. A search 
of expressed sequence tag databases also revealed the 
existence of highly conserved p19 homologs in variety of 
other evolutionarily diverse organisms such as Caenorhab- 
ditis elegans and Arabidopsis thaliana (data not shown). 
The striking conservation of p19 homologs through evolu- 
tion and the association of p19 with cyclin-CDK enzymes 
suggest that these proteins may play a fundamental role 
in regulating the growth of diverse organisms. 
Here we have identified the constituents of the cyclin 
A-CDK2 complex that predominates not only in trans- 
formed cells (VA13, 293, and HeLa) that express viral on- 
coproteins (SV40 T antigen, adenovirus E1A, and papillo- 
mavirus E6/E7 proteins), but also in transformed cells that 
express no viral proteins (e.g., ML1 and A431; Figures 1 
and 7). In an effort to identify the mechanism that results 
p19 and p45: Essential Elements of Cyclin A-CDK2 
923 
in e levated levels of  the qu inary  complex  in t rans formed 
cells, we  have examined cycl in A -CDK2 complexes  in hu- 
man f ibroblasts  that const i tut ively express  pap i l lomavi rus  
E6, E7, or  both. The express ion  of  these  viral proteins 
has been shown to cause  genomic  instabil ity, but is not 
suff ic ient to induce cel lu lar  t rans format ion  (White et al., 
1994, and re ferences  therein).  Our  data indicated that 
there was no substant ia l  e levat ion of  the cycl in A -CDK2-  
p9-p19-p45 complex  (data not shown)  in these cells. 
Therefore,  addit ional t ransformation-associated events are 
requi red for the increased level of  this complex  in trans- 
fo rmed cells. 
The p19-p45-assoc ia ted  enzyme is requi red for entry 
into S phase  both in normal  cel ls and in t rans formed cells. 
The  increased abundance  of the p45-conta in ing com- 
p lexes in t rans formed cells could  imply a part ial  deregula-  
t ion of entry into S phase.  In this way, the enhanced ex- 
press ion of  p45 in tumor  cells may contr ibute to the 
process  of  cel lu lar  t ransformat ion.  Also, the abil ity to exe-  
cute S phase  under  inappropr iate  condi t ions  could pro- 
mote the karyotypic  instabi l i ty that is a common feature 
of the t rans formed phenotype.  
Experimental Procedures 
Cells 
Human diploid cells of lung fibroblasts WI38 and IMR90, foreskin fibro- 
blast Hs68, and an SV40-transformed human fibroblast VA13 were 
obtained from American Type Cultu re Collection, The nontransformed 
cells were used between passages 13-23. HeLa, 293, ML1, A431, 
and other human cells used in the experiments were obtained from 
cell culture facilities at Cold Spring Harbor Laboratory. The cells were 
grown in Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 10% fetal bovine serum. The culture of insect Sf9 cells and the 
production of baculoviruses that encode various proteins used in the 
experiments were as described previously (7hang et al., 1994). 
Antibodies 
Antibodies raised against various cyclins and CDKs were described 
previously (Xiong et al., 1993a; Zhang et al., 1993). For the production 
of anti-p45 and anti-p19 antibodies, GST-p45 or GST-p19 (the fusion 
proteins between the GST and the full-length human p45 or p19) was 
purified from bacteria and used to immunize rabbits. For the affinity 
purifications of anti-p45 antibody, MBP-p45 (a fusion protein between 
the maltose-binding protein and p45) was purified on amylose-aga- 
rose beads (New England Biolabs). The MBP-p45 was covalently 
cross-linked to CNBr-activated Sepharose 4B beads (Bethesda Re- 
search Laboratories) and used as the affinity medium. The p45 anti- 
body was affinity purified as described previously (Xiong et al., 1992). 
The affinity purification of anti-p19, anti-GST, or anti-cyclin A antibod- 
ies was performed similarly using the bacterially produced recombi- 
nant proteins as the antigens. The affinity-purified antibodies were 
concentrated by Centricon concentrators (Amicon). 
Purification of Cyclin A-CDK2 Complex 
For the purification of cyclin A-CDK2 complex, 2 mg of affinity-purified 
anti-cyclin A antibody was loaded onto 1 ml of protein A beads (Pierce). 
After washing the column extensively with 0.1 M triethanolamine (pH 
8.3) (Sigma), the antibody was cross-linked to protein A with 50 mM 
dimethyl pimelimidate (Pierce) in 0.1 M triethanolamine (pH 8.3) at 
room temperature for 4 hr. The reaction was terminated by 0.1 M 
ethanolamine (pH 9) (Sigma) at room temperature for 2 hr. 
Actively growing suspension 293 cells, a human embryo kidney cell 
that was transformed by adenovirus DNA, were cultured in DMEM 
supplemented with 5% calf serum to 1 x 106 cells per milliliter. Typi- 
cally, 40 liters of 293 cells were pelleted and washed three times with 
phosphate-buffered saline. The cells were then lysed with 200 ml of 
lysis buffer (0.5% NP-40, 50 mM Tris [pH 7.4], 150 mM NaCI, 100 mM 
NaF, 1 mM NaVO4, and 0.5 mM PMSF) and 5 p.g/ml each of aprotinin, 
leupeptin, soybean trypsin inhibitor, and 100 mM benzamidine (all 
from Sigma). The lysate was clarified by centrifugation at 18,000 x 
g and was then loaded onto the anti-cyclin A immunoaffinity column. 
The bound proteins were released in the Laemmli sample buffer and 
separated in an SDS-polyacrylamide gel. The protein bands were 
visualized by staining with 0.05% Coomassie brilliant blue G (Sigma). 
Each individual protein band that corresponded to p19 or p45 protein 
was isolated and microsequenced as described previously (Xiong et 
al., 1993b). 
Isolation of cDNA Clones Encoding p19 and p45 
Microsequencing of p19-derived peptides produced several peptide 
sequences: K7, ENQw?EEK; K9, TFNIK; K10, NDFTEEEEAQVRK; 
K19, ?MLEDL?Mdd (small letter and question mark indicate the uncer- 
tainty of the sequence). A degenerating oligonucleotide, 5'-CGAATTCA- 
A(CT)GC(CT)TT(CT)AC(ACGr)GA(AG)GA(AG)GA(AG)GA(AG)GC-3', 
deduced from the sequence NDFTEEEEA of K10, was synthesized, 
Th is oligon ucleotide and a 20-mer of oligo(dT) specific for the 3' poly(A) 
tail were used as the primers for polymerase chain reaction (PCR) 
using a HeLa cDNA as the templates (Strategene), A 400 bp PCR 
product that contained both K10 and K7 amino acid sequences and 
the 3' untranslated region of the p19 cDNA was obtained. This DNA 
fragment was used to screen a HeLa ~.ZAP cDNA library (Strategene) 
for the full-length p19 cDNA. 
For the cloning of p45, the following peptide sequences were ob- 
tained from the p45-derived peptides: K12, ?FVIVRRPK; K13, ?LQEIP- 
DLSSNVATSF; K15, ??ELLSGMG?SALEK; K19, EEPDSENIPQEL- 
LSN; K24, ?LQVFglVP. Two oligonucleotides, 5'-CGAATrC(ACGT) 
CA(AG)AT(ACT)CC(ACGT)GA(CT)(CF)T-3', which was deduced from 
the sequence LQEIPDL of K13, and 5'-CGAATTC(CT)TC(CT)TG 
(ACGT)GG(TGA)AT(GA)TT(CF)TC-3', which was derived from the anti- 
sense direction of peptide sequence ENIPQE of K19, were synthe- 
sized. A DNA fragment that had a 147 bp insertion was obtained in 
PCR using the HeLa cDNA as the templates. This PCR product con- 
tained the known amino acid sequences of K13, K15, and K19 and 
was used subsequently as the probe to isolate the full-length p45 cD NA 
from the HeLa cDNA library. 
Immunological Procedures and Kinase Assays 
The immunoprecipitation, Western blot, kinase assays using histone 
H1 or other potential substrates, and glycerol gradient analysis were 
conducted as described previously (Zhang et al., 1994). 
Reconstitution Assay 
Insect Sf9 cells were infected with individual baculoviruses that en- 
codes either cyclin A, CDK2, p19, p45, or p9 cKs7 or p9 cKs2. The cell 
lysates were prepared from the [~S]methionine-iabeled infected cells 
as described previously (Zhang et al., 1994). For a typical reconstitu- 
tion reaction, 5 I~1 of cyclin A and 5 p.I of CDK2-containing lysates were 
mixed with 0-100 p.I of a lysate that contained either p19, p45, or both 
and incubated at 30°C in the presence of ATP as described previously 
(7hang et al., 1994). After the reaction, the protein complexes were 
isolated by immunoprecipitation a d analyzed for both protein compo- 
sition or kinase activity using histone H1 as the substrate. 
RNA Analysis and Cell Cycle Analysis 
HeLa cells were synchronized at the GIlS border by the double thymi- 
dine arrest procedure (Heintz et al., 1983; Pines and Hunter, 1990). 
Cell cycle analysis using fluorescence-activated cell sorting (FACS) 
was conducted as described previously (Xiong et al., 1993b). Northern 
blot analysis using total RNA was performed as described by Pines 
and Hunter (1990). 
Microinjection of Cells 
Microinjection experiments were conducted using the Zeiss microin- 
jection apparatus that contains the 5242 microinjector and the 5170 
micromanipulator (Eppendort) mounted on a Zeiss Aviovert-10 micro- 
scope. The femtotips were from Eppendorf (catalog number 952.008). 
All the affinity-purified antibodies were adjusted to 4 mg/ml in 100 mM 
glycine (pH 7~2). Synchronized HeLa cells were obtained by mitotic 
shake-off (Pagano et al., 1992). HeLa cells were treated with 40 ng/ 
ml nocodazole for 12 hr. The mitotic shake-off cells were removed of 
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the drug and were seeded onto a gridded glass coverslip (Bellco) 
in fresh medium. Approximately 70%-80% of cells enter S phase 
synchronously at 13-15 hr. For G1 phase HeLa cells, antibodies were 
microinjected into the cytoplasm of the cells at 6 hr postreplating, and 
the cells were labeled continuously with 10 p.M BrdU (Amersham). 
Typically, approximately 150-200 cells were injected for each sample, 
and each experiment was repeated at least three times independently. 
At 18-22 hr postreplating, the cells were fixed and immunostained 
for the injected IgG using Texas red-conjugated goat anti-rabbit IgG 
antibody (Cappel) and the FITC-conjugated mouse anti-BrdU antibody 
(Becton Dickinson) according to a method described by Leonhardt et 
al. (1992). The percentage of injected BrdU-positive cells were normal- 
ized with that of surrounding cells that were not injected. 
For S phase injection, the mitotic shake-off HeLa cells were replated 
in the presence of 10 mM hydroxyurea. At 22 hr postreplating, antibod- 
ies were microinjected into the S phase cells. Hydroxyurea was then 
removed from the medium. Cells were labeled 2 hr later with 10 mM 
BrdU for another 6 hr and then fixed for immunostaining. 
For the competition experiment, a baculovirus that is programmed 
to produce a GST-p45 fusion protein was constructed. The fusion 
protein was harvested from baculovirus-infected insect Sf9 cells and 
was purified by glutathione-Sepharose beads (Zhang et al., 1994). 
The purified protein was >95O/o pure (Figure 4B, left) and was concen- 
trated by Centricon concentrators (Amicon). The purified GST-p45 
was mixed, prior to injection, at 1:1 molar ratio with anti-p45 antibody. 
As a control, the antibody was mixed with the same glutathione solution 
that was used to elute GST-p45 protein. For the injection of nontrans- 
formed cells, low passage (10-14 passages) IMR90 human fibroblast 
cells were cultured to 70%-80% confluency. The cells were then se- 
rum-starved in DMEM without serum for 60 hr. The cells were stimu- 
lated to reenter the cell cycle by addition of 20% fetal bovine serum. 
Approximately 65°/0-70% cells reentered the cell cycle. The cells were 
microinjected at 6-8 hr poststimulation and then continuously labeled 
with BrdU for 18-20 hr. The cells were fixed and proceeded for immu- 
nostaining analysis as described above. 
For microinjection of antisense oligonucleotides, an antisense (25- 
mer) phosphorothioate oligonucleotide (S-oligonucleotide) directed 
against p45 RNA was designed (Oligos Etc.). The anti-p45 antisense 
oligonucleotide has sequence 5'-TCCTGTGCATAGCGTCCGCAG- 
GCCC-3', which corresponds to p45-encoding nucleotide sequence 
22-46. As a control, an S-oligonucleotide that had the same nucleotide 
composition as the p45 antisense oligonucleotide but with reverse 
orientation was used. The S-oligonucleotides were dissolved in 0.1 M 
glycine (pH 7.2) for microinjection. Synchronized G1 HeLa cells were 
microinjected at 6-8 hr postmitotic shake-off with 25 p.M S-oligo- 
nucleotides. To mark the injected cells, 1 mg/ml purified rabbit IgG 
protein was coinjected with the oligonucleotides. After microinjection, 
the cells were processed as described above. 
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